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Abstract
The central player in bioenergetics is the mitochondrion. Bioenergetic dysfunction is
emerging as a cornerstone for understanding the pathophysiology of mitochondrial
diseases. Accompanying the depth of mitochondrial research and the rapid develop‐
ment of mitochondrial medicine, however, is rapid amplification of the number of
mitochondrial diseases; mitochondrial dysfunction would undermine the function of
cells, tissues, and organs, thereby causing cancer, diabetes, obesity, strokes, cardio‐
vascular diseases, neurodegenerative diseases, and ageing, etc. Currently, there are
no effective treatments; Western medicine is in crisis when it comes to mitochondrial
diseases.
According to traditional Chinese medicine (TCM) theory, all kinds of diseases are born
from Qi: Qi refers to the most basic motive force and maintains life’s functional
activities. Both life and death of humans depends on Qi. Qi always underpins the basic
theory of TCM and acts as its cornerstone. Qi has been used as a healing technique in
China for 4000 years. The author proposes a scientific hypothesis that “Qi” is
“bioenergy”, that Qi-deficiency can lead to bioenergetic dysfunction, which can be
improved by Qi-invigoration, and demonstrates that Qi-invigoration was achieved
through improved mitochondrial bioenergetics. Qi-deficiency is the common cause
of mitochondrial diseases and Qi-invigoration is the basic principle for treatment of
Qi-deficiency; therefore, Qi-invigorating therapy for mitochondrial diseases is logical.
This chapter will focus on the role of mitochondrial bioenergetics in the aetiology and
progression of several mitochondrial diseases and explore the potential therapeutic
benefits of improving mitochondrial bioenergetics in mitigating the disease processes
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by Qi-invigorating therapy. It will also provide a comprehensive overview of why Qi-
invigorating therapy in TCM is suitable for mitochondrial diseases from a bioener‐
getics perspective, try to find its underlying mechanism, and to propose a novel way
of thinking and provide scientific evidence in guiding Qi-invigorating therapy for the
prevention and treatment of mitochondrial diseases.
The chapter will give an overview of some potential breakthroughs and the many
challenges remaining in pursuit of the first effective treatment for mitochondrial
disease by Qi-invigorating therapy. There seems to be light at the end of the tunnel;
efforts to develop effective drugs should be devoted to the design of Qi-invigorating
prescriptions that work in synergy to protect the mitochondria. It is hoped that the
next few years will see a further convergence of Qi-invigorating therapy with
mitochondrial bioenergetics, which will provide a comprehensive view of mecha‐
nisms on mitochondrial diseases. It seems likely that we are on the right track to
acquiring this understanding, and that it will involve mechanisms rich with ideas
from both the modern bioenergetics and the old Qi-invigorating therapy in TCM on
mitochondrial diseases and how to counteract them.
Keywords: Qi-invigorating therapy, mitochondrial diseases, bioenergetics, mito‐
chondria, energy metabolism
1. Introduction
As we all know, traditional Chinese medicine (TCM) is the summary of Chinese people’s
experiences in fighting diseases for thousands of years. Its theoretical system contains the
essence of Chinese classical philosophy, embodies the Chinese people’s own culture and
profound speculative dialectical relationship between man and nature, and has made a great
contribution to the healthcare of the Chinese people and the prosperity of the Chinese nation.
TCM is also a unique treasure of the world’s medical knowledge, and contributed to world
civilization via the Silk Road and other external communication channels from very early on.
With the changes of the concept of people’s health and the transformations of medical models
in recent years, TCM pays more attention to the “preventive treatment of disease” and follows
the “overall theory, system theory”. It has ushered in a new development, not only having a
significant effect on many common diseases but also plays an important role in the prevention
and treatment of major incurable diseases and emerging infectious diseases, providing a source
of knowledge and technology, and research and development ideas, for the development of a
modern pharmaceutical industry and health services, and the evolution of medical science.
In the development of medical and health services with Chinese characteristics, the Chinese
government has adhered to the policy of juxtaposing Chinese and Western medicines. The
practice proves that the two medical systems have complementary advantages, promote each
other. Both systems have salient features and advantages for China’s medical and health
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protection, and not only provide a unique impetus for the development of Chinese medical
science, but also play an increasingly significant role for the realization of a healthy China.
TCM is a treasure, this ancient wisdom should be respected and applied to the modern medical
system; it will provide more choice and a wider field of vision for modern medicine at the two
cognitive crossroads of East and West.
The mitochondria, whose main function is the production of the energy substance adenosine
triphosphate (ATP), and are the hub and core of all life’s activities, have been recognized as a
cellular “Achilles heel”. Interest in the roles that mitochondria play in human health and
disease have grown markedly over the past two decades. Mitochondria lie at the heart of
systemic metabolic regulation, they regulate the life and death of cells by manipulating several
factors, including bioenergetics, mitochondrial permeability transition (MPT), and mitochon‐
drial redox status. They are usually regarded as specialized organelles for cellular respiration
and oxidative phosphorylation (OXPHOS). A lack of cellular energy, excessive free radical
production, and dysregulated apoptosis are found alone or in combination in most human
diseases, including neurodegenerative diseases, strokes, cardiovascular disorders, ischemia/
reperfusion, and cancer [1].
Mitochondrial dysfunction has severe cellular consequences and is linked to ageing and
mitochondrial diseases in humans. Since the discovery of the first case of mitochondrial disease
in 1962 [2], the depth and development of mitochondrial research and medicine has increased
rapidly, as has the number of mitochondria-related diseases; mitochondrial dysfunction
would undermine the function of cells, tissues, and organs, thereby causing cancer, diabetes,
obesity, strokes, cardiovascular diseases, age-related diseases, neurodegenerative diseases,
and ageing, etc. Mitochondria have become a new target for the treatment of diseases, and
mitochondrial dysfunction was listed as one of the nine hallmarks of ageing in the journal Cell
in 2013 [3]. Therefore, mitochondrial protection is an important mechanism for the treatment
of mitochondrial diseases.
Currently there are no highly effective mitochondrial disease treatments. Though related
symptoms, such as seizures or attention problems can be managed with various medications,
the mitochondrial disease itself is unchanged. As scientists have learned more about mito‐
chondria’s role in health and in disease, research suggests that mitochondrial function may be
the unifying theme — the Holy Grail of medicine, perhaps — of understanding a spectrum of
diseases, conditions, and why we grow old. Mitochondrial research across different disease
disciplines will help all of us access treatments, and ultimately cures, much faster.
Continually increasing resources are being expended to combat mitochondrial diseases. Yet
the causes of these diseases remain a mystery, while their incidence and morbidity either
remain constant or are increasing. Huge investments in biomedical research in recent years
have resulted in some striking accomplishments, but have failed to reveal the anticipated
causes for the diseases. Western medicine is in crisis [4].
1.1. Mendelian paradigm of genetics and mitochondrial diseases
Western biomedical science has stood on two philosophical pillars: the anatomical paradigm
of medicine and the Mendelian paradigm of genetics. The Mendelian paradigm of genetics
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argues that genetic traits are transmitted across generations according to the laws of Gregor
Mendel. However, Mendelian genetics is specific for nuclear DNA (nDNA) genes and have
been powerful predictors of medical relationships for the past century, but fails to direct us
toward answers for mitochondrial diseases. Since mitochondrial DNA (mtDNA) encodes
genes for proteins of energy metabolism, human diseases affect many organs that could
originate from systemic energy metabolism defects and could result from mutations in mtDNA
[4]. The classical Mendelian genetic perspective has failed to explain the aetiology of mito‐
chondrial diseases, because they are primarily systemic bioenergetic diseases, and the most
important energy genes are located in mtDNA [5].
1.2. mtDNA and mitochondrial bioenergetics
In  many  animal  species,  mtDNA  is  a  circular  intron-free  genome  consisting  of  14,000–
17,000 base pairs (16,569 in humans), although in some species it is much larger, noncircu‐
lar, and contains introns [6–7]. It is typically maternally inherited and present in multiple
copies within each cell; the mtDNAs are grouped in DNA-protein complexes referred to as
nucleoids [8–9] that are anchored to the inner mitochondrial membrane. Most somatic cells
in mammals have 103–104  mtDNAs [10], but this number varies significantly by cell type
and developmental stage [11].
Mitochondria are at the centre of bioenergetics and generate about 90% of cellular energy,
regulate cellular redox status, and produce reactive oxygen species (ROS). The mitochondrial
genome consists of thousands of copies of mtDNA, plus between 1,000 and 2,000 nDNA genes.
mtDNA codes for 13 OXPHOS polypeptides, the 22 tRNAs, and the 12S and 16S rRNAs.
mtDNA polypeptides encompass seven of OXPHOS complex I (ND1, ND2, ND3, ND4, ND4L,
ND5, and ND6), one of complex III (cytochrome b), three of complex IV (COI, COII, and COIII),
and two of complex V(ATPase6 and ATPase8). Consequently, mitochondrial biology and
genetics become excellent candidates for expanding the anatomical and Mendelian paradigms
to address the complexities of age-related diseases, ageing, and cancer [12], and life involves
the interplay between structure and energy [4].
Both variation in the mtDNA and nDNA-coded mitochondrial genes sequences can perturb
mitochondrial bioenergetics and result in disease. Since different tissues depend on mitochon‐
drial energy to different extents, partial systemic energy deficiency can result in tissue-specific
symptoms. Tissues with high energy demands include the brain, heart, muscles, kidneys, and
the endocrine system: the organs commonly affected in metabolic and degenerative diseases
[5]. A decline in energy is common in ageing, and the restoration of mitochondrial bioener‐
getics may offer a common approach for the treatment of numerous age-associated diseases
[13].
The basic role of mitochondria in sustaining the normal cellular function has made dysfunction
of this organelle a central feature of numerous diseases in any organ system at any stage of life
[14–15]. ‘‘Mitochondrial medicine’’ has emerged as an active field of research. However, the
mystery remains as to how tissue or cell type specificity occurs, and how a systemic disorder
of one mitochondrial complex can cause a selective disease phenotype while leaving other
tissues intact. It is believed that many of the mitochondrial diseases might actually be an
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expression of progressive organ system failure due to disruption of specific aspects of
mitochondrial function. Even though dysfunctional mitochondria appear to be a common
underlying problem for all these diseases, they each exhibit unique triggers and symptoms.
1.3. Mitochondrial dynamics and bioenergetics
Mitochondria are highly dynamic organelles that show constant movement, fusion, and fission
[16–17]. The role of mitochondrial dynamics is enabling content mixing of mitochondrial
matrix and membranous components between mitochondria [18]. Disruption of mitochondrial
dynamics causes a series of diseases, including neurodegenerative disease, cardiovascular
disease [19], and even cancer [20]. Benard et al. describe the fundamental mechanisms by which
mammalian cells regulate energy production, and put emphasis on the importance of mito‐
chondrial dynamics for the regulation of bioenergetics. In addition, most neurodegenerative
diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease
(HD), and Hereditary Spastic Paraplegia are associated with defects in mitochondrial dynam‐
ics and bioenergetics [21]. Therefore, to unravel the fundamental mechanisms by which
mitochondrial form interacts with mitochondrial function could permit us to increase our basic
knowledge on the regulation of energy metabolism and to decipher the pathophysiology of a
group of rare neuronal diseases.
Pathogenic mutations in genes essentials for mitochondrial fusion and fission have compli‐
cated the mechanisms of these diseases [22]. Thus, the mitochondrial network organization is
a new parameter for physiopathological analyses of mitochondrial diseases [21]. The possible
interaction between mitochondrial dynamics and energy production could offer an opportu‐
nity for the discovery of drugs that target mitochondrial fusion or fission with a stimulatory
effect on energy metabolism, to the benefit of patients suffering from mitochondrial diseases
[23–24].
1.4. Qi-invigoration and mitochondrial bioenergetics improvement
In TCM, “Qi” is expressed as the basic material that constitutes the body, maintains human
life activities, and is its basic driving force. Qi, as the master of the brain, regulates Yin-Yang
and five elements, tonifies the five vital organs of the human body, and keep the six hollow
viscera unobstructed, and is in charge of chemical and biological transformation and defences,
Qi dominate the whole vital activities. Qi is the centre in TCM from basic theory to clinical
practice. According to TCM, “Qi is the root of the human”; “All the diseases originate from
Qi”; “Both life and death depend on Qi, if Qi gets together, it will result to the birth; if Qi is
strong, then the human body is healthy; if Qi is waning, the body will be weak; if Qi is
disordered, the human will be sick; if Qi is depleted, the human will die”. This shows that Qi
is closely related to health, disease, and life.
Qi can make the human body work in an orderly fashion by promoting a variety of physio‐
logical activities; “Qi-deficiency” will lead to a decline of physiological functions. As one part
of a central medical classic The Yellow Emperor’s Inner Canon, ‘Plain Questions’ pointed out that
consumption of the vital essence Qi leads to deficiency, ‘Miraculous Pivot’ says that Qi-
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deficiency in the heart, liver, spleen, lung, or kidneys becomes worse with increasing age, and
ultimately all five internal organs of the body become deficient, spirit and Qi leave the body,
and eventually the human will die. The basic idea of TCM to prevent and cure diseases is
strengthening vital Qi to eliminate pathogenic factors. Strengthening vital Qi can improve
body’s resistance to disease, in order to eliminate weakness syndromes, ward off illnesses, and
be physically strong. On the understanding of the aetiology, TCM theory emphasizes the cause
of disease — “vital Qi-deficiency”, especially.
Due to the fact that both Qi and bioenergy are at the centre of life activity, the author suggests
that Qi and bioenergy are closely related, and proposes a scientific hypothesis that “Qi” is
“bioenergy” [25]; that Qi-deficiency can lead to mitochondrial energy metabolism obstacles,
which can be improved by Qi-invigoration; and demonstrates that Qi-invigoration can be
achieved through improved mitochondrial bioenergetics [26]. Qi-deficiency is the common
cause of a variety of diseases (including mitochondrial diseases) and Qi-invigoration is the
basic principle for the treatment of Qi-deficiency. Doctors of TCM usually compose prescrip‐
tions made up of Qi-invigorating herbal medicines (QIHM) for Qi-deficiency, and have
accumulated abundant clinical experience for a long time. QIHM is a group of herbal medicines
which can invigorate Qi and treat syndromes of Qi-deficiency.
1.5. The central premise of the chapter
This chapter will examine the role of mitochondrial bioenergetics in the aetiology and
progression of several mitochondrial diseases and explore potential therapeutic benefits of
improving mitochondrial bioenergetics in mitigating the disease processes by Qi-invigorating
therapy. The chapter aims to provide a comprehensive overview of why Qi-invigorating
therapy in TCM is suitable for mitochondrial diseases from a bioenergetic perspective, try to
find its underlying mechanism, and provide a novel way of thinking and scientific evidence
in guiding Qi-invigorating therapy for the prevention and treatment of mitochondrial diseases.
2. Mitochondrial bioenergetics dysfunction and diseases
2.1. A Primer on mitochondrial bioenergetics
The standard model of mammalian cellular bioenergetics is based on the pioneering work of
Krebs and Mitchell over half a century ago [27]. In 1961, Peter Mitchell published a unique
hypothesis regarding cellular bioenergetic conservation, to elucidate the role of mitochondria
in energy generation — Mitchell theory, namely the chemiosmotic theory of OXPHOS, is one
of the most fascinating discoveries in the history of science. ATP synthase was driven to
produce ATP by the transmembrane proton gradient induced when electrons transfer along
a series of respiratory enzyme complexes in the mitochondrial inner membrane, an insight for
which Mitchell was awarded the Nobel Prize in Chemistry in 1978 [28]. Studies on bioener‐
getics have occupied an important position in the life sciences, the generation mechanism of
ATP (the most important energy molecule in life activity) was elucidated by an academic of
the National Academy of Sciences — Boyer — who proposed binding change and rotational
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catalysis mechanism of ATP synthase, and won the 1997 Nobel Prize in Chemistry. Products
of the Krebs cycle, such as nicotinamide adenine dinucleotide (NADH) and succinate, are the
obligatory factors that drive mitochondrial electron transport and maintain OXPHOS and ATP
production (Figure 2) [27]. Mitochondrial bioenergetic processes are central to the production
of cellular energy, and a decrease in the expression or activity of enzyme complexes responsible
for these processes can result in an energy deficit that correlates with many metabolic diseases
and ageing [29].
An increase in the slippage of complex I and III of the electron transport chain (ETC) [30–32]
can lead to overproduction of ROS, which can further damage the mtDNA and create a vicious
feed-forward loop of energetic decline. The consequence of such an energetic decline is
potentially grave, which might be manifested as either the normal progression of ageing, or
as the onset of major diseases such as diabetes, AD, PD, and cancer [33–34]. Interest in the roles
that mitochondria play in health and disease has grown markedly over the past two decades
[35]. Mitochondria are involved both in male and female germ-line formation, which may also
be affected by sexual antagonism of mitochondrial-nuclear gene interaction. Mitochondrial
energy metabolism is also involved in tissue and organism differentiation. The mitochondrial
bioenergetics system should be recognized as a candidate key driver of speciation events, at
least in animals [36].
Cardiolipin is a unique phospholipid which is almost exclusively located in the inner mito‐
chondrial membrane, where it is biosynthesized. Cardiolipin plays the functional role in
several reactions and processes involved in mitochondrial bioenergetics [37]. Cardiolipin
contains unsaturated fatty acyl chains which are readily oxidizable targets. Peroxidation of
cardiolipin is now considered an important event in mitochondrial dysfunction in cellular
pathophysiology and also an early step in apoptotic cell death. Abnormalities in cardiolipin
content, fatty acyl chain composition, and remodelling appear to be, at least in part, responsible
for mitochondrial dysfunction associated with several pathophysiological situations, includ‐
ing hypo- and hyperthyroid states, heart ischemia/reperfusion, heart failure, diabetes, Barth
syndrome, as well as ageing and age-related cardiovascular and neurodegenerative disorders.
Pharmacological strategies designed to prevent cardiolipin oxidation may open new perspec‐
tives for treatment of these disorders [37].
High-fat feeding is associated with reduced whole body respiration and, over sufficient
duration, results in reduced mitochondrial respiration and ATP production. High-fat feeding
also results in more ROS per unit respiration and per unit ATP being produced. The impaired
high-fat-induced bioenergetics is, in part, mitigated by partial substitution of n-3 fatty acids
in the diet [38]. Most of the beneficial effects of melatonin in a number of physiopathological
situations, which may depend on its effect on mitochondrial bioenergetics, involve mitochon‐
drial dysfunction as a primary cause of disease [39].
2.2. Mitochondrial bioenergetic dysfunction
Bioenergetic dysfunction is emerging as a cornerstone for understanding the pathophysiology
of cardiovascular disease, diabetes, cancer, and neurodegeneration. A substantial bioenergetic
reserve capacity of cells is a prospective index of ‘healthy’ mitochondrial populations, which
appears to be essential for cell survival under conditions of pathological stress [40].
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It has long been known that mitochondria show a diminished functional activity when isolated
from a broad range of tissues subjected to pathological stress. Well-established examples are
alcohol-dependent hepatotoxicity, cardiac ischemia/reperfusion, and neurodegenerative
diseases [41–43]. In all of these cases, a role for reactive oxygen or nitrogen species (ROS/RNS)
in causing mitochondrial dysfunction has been proposed. Typically, mitochondrial damage is
defined as a relative decrease in respiratory parameters, such as a change in oxygen consump‐
tion in the presence of substrates and ADP (state 3 respiration), in the presence of substrates
alone (state 4), or the ratio of these parameters (i.e., respiratory control ratio (RCR)). Other
parameters include decreased activity of specific enzymes, deletions in mtDNA, and increases
in oxidative markers such as protein oxidation. The challenge with these data is in integrating
them into an overall model of cellular and tissue bioenergetic function. It is becoming apparent
that mitochondria under pathological stress exhibit multiple defects that overall can be viewed
as a decrease in mitochondrial quality [43–44].
An existing mitochondrial population is examined that was subjected to pathological stress
with the formation of reactive oxygen, nitrogen, and lipid species (ROS/RNS/RLS). This
oxidative stress damages mtDNA, impairing the ability of the organelle to replace damaged
electron transport proteins and decreasing bioenergetic reserve capacity; the resulting
increased mitochondrial ROS then oxidatively damage previously unmodified mitochondria.
The damaged mitochondria are turned over by a mitophagic mechanism that then suppresses
this vicious cycle. The mitochondrial population is now renewed through mitochondrial
biogenesis. The bioenergetic reserve capacity is essential for resistance to oxidative stress and
supplying ATP demand. Once the bioenergetic reserve is depleted, bioenergetic failure occurs
and the cell is programmed for cell death [40].
A unique feature of the molecular machinery controlling cellular bioenergetics is that the
proteins necessary for electron transport and OXPHOS are encoded by both nuclear and
mitochondrial genomes. An emerging concept in the energetics field is that the reserve capacity
can be used as an index of mitochondrial health [45–47]. It appears that a higher bioenergetic
reserve capacity results in a greater ability to withstand oxidative stress [40].
The mitochondrial genome encompasses in the order of one to two thousand nDNA genes and
thousands of copies of the mtDNA. Hence, a large number of mitochondrial gene targets can
mutate and have significant effects on cellular bioenergetics. Given that a human has in the
order of 1017 mitochondrial capacitors, this is a great deal of potential energy, the vital force
that animates our life. When breathing stops, the membrane potential collapses, energy
transduction ceases, and death ensues [48–51]. However, there is a clear need to determine
whether the contribution of mitochondrial dysfunction to different age-related diseases is
explained by a cellular bioenergetic deficiency or by changes in mitochondrial ROS production
affecting oxidative damage and signalling [52].
2.3. Bioenergetics and disease
2.3.1. mtDNA mutation and mitochondrial heteroplasmy
The mitochondrial genome encompasses both mtDNA and nDNA genes and the assembly
and function of mitochondrial OXPHOS requires the cooperation of both genomes. Hence, the
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interaction of the Mendelian and non-Mendelian mitochondrial genes generates a ‘‘complex
genetics’’ that nicely explains many of the hereditary anomalies of many ‘‘common’’ clinical
problems. Moreover, the central importance of energy metabolism for health provides a direct
explanation of the pathophysiology of many diseases [53]. The frequency of mtDNA diseases
is indeed high, currently estimated as having an incidence of 1.65/10,000 [54]. Moreover,
mtDNA mutations have been linked to a broad spectrum of clinical problems affecting the
central nervous system, the heart and cardiovascular system, the musculoskeletal system, and
the renal and endocrine systems — many of the same systems that are affected by ageing and
the age-related diseases. The appearance of a new mtDNA mutation in a cell results in an
intracellular mosaic of mutant and normal mtDNAs, a state known as heteroplasmy. Identical
twins derived from the same heteroplasmic egg can have different mtDNA genotypes and
different clinical phenotypes and manifestations [4].
Rodell et al. present the contrasting view that the effects of mitochondrial heteroplasmy, in a
broader sense, are not limited to a decline from a healthy norm, leading to unhealthy ageing
and disease, but may also serve as the fabric of positive adaptive responses, at the genetic and
epigenetic levels, to challenging bioenergetic events. The roles of mitochondrial biogenesis and
dynamic fission and fusion mechanisms are vital to the maintenance of healthy mitochondrial
populations, and impairment of the respective mechanisms is implicated in many age-related
diseases [55]. Recently, Jose et al. reviewed the adaptive biology of mitoplasticity as a protective
mechanism against ageing, diabetes, cancer, and neurodegenerative diseases, which Rodell et
al. extend to the specific and directed promotion of healthy ageing [55–56].
Ageing is associated with decreasing bioenergetic capacity, as mitochondria increasingly
become unable to meet the respiratory energy demands of cells [57]. Free radicals increasingly
damage mtDNA with age, leading to an age-dependent state of variable heteroplasmy in
individual cells, with detrimental effects on the bioenergetic capacity of the tissue [58]. Studies
of mtDNA mutator mice show that increased accumulation of damaged mtDNA exacerbates
the heteroplasmic conversion, with rapid onset of unstable health as the hallmark of ageing
and the onset of age-related diseases. Such heteroplasmic variation can be described as the
consequence of an age-dependent lack of selection [59].
2.3.2. Bioenergetic deficiency for mitochondrial diseases
The role of mitochondria in mitochondrial diseases aroused people’s concern due to the
central role of mitochondria in producing chemical energy (ATP) to meet cellular require‐
ments. Old mitochondria appear morphologically altered and functionally produce more
ROS and less ATP. Mitochondrial bioenergetic processes are central to the production of
cellular energy, and energetic deficit correlates with many metabolic diseases and ageing.
As the mutant mtDNAs accumulate, they progressively erode the individual cell’s energet‐
ic  capacity.  Ultimately,  cellular  energetics  drops  below the  threshold necessary  for  nor‐
mal cellular and tissue function, and leads to a decline in organ function, tissue failure, and
an ageing phenotype [12,60].
While mitochondrial defects are systemic, the clinical manifestations are often organ specific.
This is because different organs and tissues have different needs and roles in energy homeo‐
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stasis. Certain tissues require high levels of mitochondrial ATP, such as the central nervous
system, the heart, and the muscles. These organs are preferentially affected as mitochondrial
energy production declines. Other tissues store energy in fat. The liver is an energy homeostatic
tissue, maintaining the serum glucose level within acceptable limits [49].
Mitochondrial disease or dysfunction (a cellular energy deficiency problem) is at the root of
all these diseases. It is generally accepted that minimizing mitochondrial dysfunction is of
central importance in maintaining cellular and body’s fitness and also in counteracting
mitochondrial diseases. The chapter may hold an important key to understanding mitochon‐
drial disease (i.e., the body cannot make enough energy, or ATP). Mitochondrial diseases
primarily affect the brain, heart, and muscle tissues at varying levels of severity. Almost all
cells in the body have mitochondria, which are tiny “power plants” that produce the body’s
essential energy. When someone has mitochondrial disease, their power plants do not work
properly and some functions in the body (e.g., muscles and neurological pathways) do not
work normally. The body can have a power failure similar to a “brown out” or a “black out”.
Mitochondria are highly dynamic organelles which play a central role in cellular homeostasis.
Mitochondrial dysfunction leads to life-threatening disorders and accelerates the ageing
process. A common denominator of these lifespan-modulating interventions seems to be
defined by their ability to impact on cellular energy metabolism and stress response [61].
Alterations in mitochondrial structure and function, nDNA, and/or mtDNA mutations can
impair OXPHOS, which in turn can reduce energy production, alter the cellular redox state,
increase ROS production, deregulate Ca2+ homeostasis, and ultimately activate the mitochon‐
drial permeability transition pore (MPTP), leading to apoptosis. The consequences of OXPHOS
perturbation result in decline of mitochondrial function, and energy output declines, which
accounts for ageing, degenerative diseases, metabolic deregulation, endocrine dysfunction,
and symptoms such as diabetes, obesity, and cardiovascular disease. As inflammatory
response initiates, this will contribute to autoimmune diseases. Finally, cancer cells must
manage energy resources to permit rapid replication [5] (Figure 1).
The milder mtDNA variants can also affect caloric metabolism and result in metabolic diseases,
such as diabetes and obesity, and degenerative diseases, such as psychiatric disorders,
Parkinson’s disease (PD), and Alzheimer’s disease (AD). The more severe mtDNA mutations,
like MERRF (myoclonus epilepsy with ragged red fibres) and MELAS (myopathy, encephal‐
opathy, lactic acidosis, stroke-like episodes), cause progressive multisystem diseases, fre‐
quently resulting in premature death. The most severe mtDNA mutations can lead to lethal
childhood diseases, such as Leigh syndrome [62].
While mtDNA mutations have permitted humans to adapt to stable regional environmental
energetic differences, many energy resources and demands fluctuate cyclically, for example,
seasonal changes in temperature and food supply. As these mitochondrial bioenergetic
parameters fluctuate with the environment, they drive posttranslational modification of the
proteins of the epigenome and the signal transduction pathways. In this way, the expression
of nDNA-coded bioenergetic genes is coupled to environmental changes through mitochon‐
drial energy flux [63–64]. This new bioenergetic perspective not only provides a framework
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within which the genetics and pathophysiology of “complex” diseases, such as PD, AD, autism
spectrum disorders (ASDs), and psychiatric disorders [5] can be re-evaluated, it also provides
a coherent theory for the aetiology of the “complex” metabolic and degenerative diseases,
suggesting powerful new approaches for their presymptomatic diagnoses, reliable prognosis,
and effective treatment and prevention.
3. Mitochondrial diseases
Enormous strides have recently been made in our understanding of the biology and pathobi‐
ology of mitochondria. Many diseases have been identified as having been caused by mito‐
chondrial dysfunction, and many pharmaceuticals have been identified as previously
unrecognized mitochondrial toxicants. Meyer et al. reviewed the importance of mitochondrial
function and maintenance for health based on the genetics of mitochondrial diseases and the
toxicities resulting from pharmaceutical exposure [11]. There are, however, currently no
pharmaceutical cures for any mitochondrial disease [65].
The diseases described above are unambiguously caused by mitochondrial dysfunction. There
are also many very common diseases for which there is strong correlative evidence suggesting
that mitochondrial dysfunction is at least partially causative [50]. These are frequently diseases
of old age or energy homeostasis and include neurodegenerative diseases such as PD and AD
Figure 1. Bioenergetic paradigm for metabolic and degenerative diseases, cancer, and ageing. Figure adapted from ref‐
erence [5].
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[42], many cancers [34,66], diabetes, metabolic syndrome, cardiovascular disease [67], and
others [68]. Considerable effort is currently devoted to investigate whether these relationships
are causal. There is experimental evidence demonstrating that defective mtDNA replication
and repair can accelerate organismal ageing [52].
The existence of so many mitochondrial diseases illustrates the critical importance of mito‐
chondria for health. Why did it take us so long to realize that many diseases are in fact
mitochondrial diseases? Part of the answer is surely that they are very complicated, although
they often target tissues with high energy use, and there is significant variability in their
presentation. Some mtDNA mutations result in single-tissue diseases, others affect a wide
spectrum of tissues, and others affect different tissues in different patients, with varying ages
of onset [69]. However, the absence of fundamental knowledge about the biology and genetics
of the mitochondrion limited a deeper understanding of the inheritance and pathophysiology
of mitochondrial diseases.
3.1. Classic mitochondrial disorders
Classic mitochondrial disorders result from mutations in mtDNA or nuclear genes that disrupt
mitochondrial respiratory function. These diseases typically have brain and skeletal muscle
manifestations, and therefore they are often referred to as mitochondrial encephalomyopa‐
thies. Based on the tissues typically affected in mtDNA diseases, it is generally thought that
tissues such as brain, skeletal muscle, heart muscle, and endocrine glands are particularly
dependent on respiratory function and have a lower bioenergetic threshold [70].
Leber’s hereditary optical neuropathy (LHON) and mitochondrial myopathies were in 1988
the first diseases demonstrated to be caused by mtDNA mutations [71–72]. There are now more
than 200 such diseases, including MELAS, MERRF, and many others [73]. Importantly, cellular
dysfunction and clinical disease do not occur until a threshold proportion of mtDNAs carrying
mutations (heteroplasmy) is reached [74–75]. Together, these diseases affect at least 1/10,000
people clinically [76], establishing mtDNA mutations as a major cause of disease.
Most patients with mtDNA diseases caused by deletions that cross two or more gene boun‐
daries (intergenic mutation) generally do not reproduce. Therefore, most intergenic mutations
arise de novo, resulting in sporadic disease [71]. Common presentations of this class of diseases
include chronic progressive external ophthalmoplegia (CPEO) and the Kearns-Sayre syn‐
drome (KSS) [77]. In contrast, most maternally inherited mtDNA diseases are the result of
mutations confined within the gene commonly involving one or few base changes (intragenic
mutations). Examples of this latter class of mtDNA mutations include LHON [72], MERRF
syndrome [78–79], and neurogenic muscle weakness, ataxia, retinitis pigmentosum (NARP),
and Leigh syndrome [80]. Over 200 pathogenic mtDNA base substitution mutations associated
with a broad spectrum of clinical phenotypes have been identified, including encephalomy‐
opathy, mitochondrial myopathy, exercise intolerance, gastrointestinal syndromes, dystonia,
diabetes, deafness, cardiomyopathy, AD, and PD, etc [81].
In addition to recent deleterious mutations and ancient adaptive mtDNA variants, somatic
mtDNA mutations play an important role in human health. Moreover, somatic mtDNA
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intergenic and intragenic mutation levels are elevated in the organs of patients with degener‐
ative diseases. The accumulation of somatic mtDNA mutations causes an age-related decline
in mitochondrial function, thus exacerbating partial inborn defects in mitochondrial function
leading to the delayed onset and progression course of age-related diseases [53]. Experimental
results from mtDNA mutator mice suggest that mtDNA mutations in somatic stem cells may
drive progeroid phenotypes without increasing oxidative stress, thus indicating that mtDNA
mutations that lead to a bioenergetic deficiency may drive the ageing process [52]. Thus,
somatic mtDNA mutations provide the ageing clock. Large-scale deletions in some cell types
can attain a threshold to directly affect OXPHOS. Single-cell studies have shown that deletions
can occur in ~32 to 80% of mtDNA molecules in substantia nigra neurons of brains from patients
with PD [82].
Since most mitochondrial proteins are nuclear encoded, it is not surprising that mutations in
many nuclear genes also cause mitochondrial diseases. For example, mutations in DNA
polymerase γ — the only mtDNA polymerase and thus responsible for all mtDNA replication
and repair — cause a wide range of mitochondrial diseases including progressive external
ophthalmoplegia, and Leigh’s syndrome, among others [83]. Friedreich’s ataxia is caused by
mutations in the gene encoding frataxin which is involved in iron-sulphur cluster assembly
[84]. Diseases caused by mtDNA and nDNA mutations are estimated to collectively have an
incidence of ~1/4000 individuals [85–86].
These and related studies will permit determination of exactly how important the mitochon‐
drial and mtDNAs are in determining the complex physiology and inheritance of the common
‘‘complex’’ metabolic and degenerative diseases that demand much of the healthcare resources
in both developing and developed countries.
3.2. Mitochondria and cardiovascular diseases
Cardiovascular disease remains the commonest form of mortality and morbidity in the
Western world. There remains an urgency to identify and translate therapies to reduce the
effects of this disease and its associated co-morbidities. Vascular smooth muscle cells are the
primary source of extracellular matrix and collagen, and it has been suggested that loss of
viability and vitality of these cells contributes to plaque vulnerability and rupture. It is the loss
of ATP that may ultimately be more detrimental. Finding alternative sources of ATP synthesis
by energetic reconfiguration may also provide a vital link in delaying the kinetics of plaque
rupture [87].
Excitation–contraction coupling in cardiac myocytes consumes vast amounts of ATP that need
to be replenished by OXPHOS. During a single heartbeat, ~2% of the cellular ATP is consumed,
and the whole ATP pool of cardiac myocytes is turned over within one minute. To orchestrate
OXPHOS in response to constantly changing workloads of the heart, constant availability of
ATP must be secured [88].
A large body of work has shown that endothelial dysfunction contributes to the pathogen‐
esis  of  cardiovascular disease,  and considerable effort  has been put into defining opera‐
tive  mechanisms.  Recent  work  has  emphasized  the  importance  of  mitochondria  for
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endothelial function. Although they have long been recognized for their role in bioenerget‐
ics, mitochondria participate in a host of other cellular processes. It is now recognized that
endothelial mitochondria play a prominent role in signalling cellular responses to environ‐
mental cues. An important mode of mitochondrial signalling is the regulated production
of  ROS.  Blood  markers  of  mitochondrial  dysfunction,  such  as  mtDNA  damage  and
mitochondrial  oxygen  consumption  in  circulating  leukocytes  or  platelets,  may  facilitate
studies of systemic abnormalities of mitochondrial function and their relation to cardiovas‐
cular disease [89]. The presented studies suggest that mitochondria-directed therapies have
potential  for  the  prevention  and  management  of  cardiovascular  disease,  in  part  by
improving mitochondrial function in the endothelium.
3.3. Mitochondria and metabolic diseases
Metabolic syndrome is a growing epidemic in the United States and worldwide. Currently,
approximately 34% of the US population are living with this diagnosis [90–91] and it is
expected that this number will continue to increase. One of the hallmarks of metabolic
syndrome is central obesity, an increase in visceral white adipose tissue (WAT) around the
midsection. Central obesity not only contributes to metabolic syndrome but also increases
individual risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease [92].
3.3.1. Obesity
An excess consumption of high-calorie foods appears to be one of the key factors in the
epidemic of obesity [93], which increases the risk for developing diseases with a bioenergetic
component [94]. As described above, these include cardiovascular disease [95], hepatotoxicity,
and neurodegenerative diseases. While a high caloric intake can be offset by exercise (for
example, the gold medallist Michael Phelps remains lean despite consuming up to ~12,000
calories per day), increasing evidence suggests that physical activity, on average, is declining
[95]. This has led to heightened efforts to promote increased energy utilization and to better
understand how altered intermediary metabolism, perturbations in cellular bioenergetics, and
genetic differences contribute to the risk for becoming obese and insulin resistant [40].
Obesity is a primary risk factor for numerous metabolic diseases including metabolic syn‐
drome, T2DM, cardiovascular disease, and cancer. Although classically viewed as a storage
organ, the field of white adipose tissue biology is expanding to include the consideration of
the tissue as an endocrine organ and major contributor to overall metabolism. Given its role
in energy production, the mitochondrion has long been a focus of study in metabolic dys‐
function, and a link between the organelle and white adipose tissue function is likely [90].
Physical exercise is a promising strategy to counteract liver mitochondrial damage [96–98].
Exercise is considered a non-pharmacological tool against several lifestyle disorders in which
mitochondrial dysfunction is involved. Both exercise types (voluntary physical activity and
endurance training) counteracted oxygen consumption (RCR, P/O ratio, and FCCP-uncou‐
pling state) impairments and improved mitochondrial membrane potential (Δψm) (lag-phase).
In conclusion, exercise prevented or reversed the bioenergetic impairment induced by non-
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alcoholic steatohepatitis, and both prevents and mitigates non-alcoholic steatohepatitis-
induced liver mitochondrial structural and bioenergetic impairments [96].
Mitochondria lie at the heart of systemic metabolic regulation. They act as end-point regulators
of metabolic rate and affect thermogenesis primarily by increasing proton leak. In brown fat,
the relatively high expression of uncoupling protein 1 (UCP1) allows re-entry of protons into
the mitochondrial matrix without generating ATP. This uncoupling therefore generates an
increase in substrate utilization and ETC turnover, as well as energy in the form of heat [99].
Despite the low amounts of brown fat in humans, as little as 50g of brown fat has been estimated
to be capable of utilizing up to 20% of basal caloric needs [100]. This suggests that decreasing
mitochondrial efficiency is an attractive therapeutic option for obesity [40].
3.3.2. Diabetes Mellitus (DM)
DM is  a  common degenerative disease and one of  the leading causes of  morbidity and
mortality in developed countries.  DM is  a  heterogeneous disease,  affecting nearly every
organ in the body. It has a common phenotype of impaired glucose tolerance and can be
divided  in  type  1  (T1DM) and type  2  (T2DM).  T1DM occurs  mainly  in  childhood and
puberty  and  is  characterized  by  an  absolute  insulin  deficiency,  requiring  daily  insulin
replacement therapy. T2DM usually develops in adults over the age of 40, accounts for 90–
95% of all DM cases and is characterized by insulin resistance and/or inadequate compen‐
satory insulin secretion response [101–102].
DM has become a worldwide epidemic with a substantial social and economic burden [103].
The  prevalence  of  this  disorder  is  rising  dramatically;  an  estimated  370  million  people
worldwide will be suffering from diabetes in 2030 [104]. Among the wide range of chronic
complications associated with diabetes, brain degenerative events, cognitive deterioration,
and dementia have assumed pivotal importance in the last few decades [105]. In particu‐
lar,  diabetes is  considered to be a major risk factor for the development of  AD and PD
[106–107].  Mitochondria  take  centre  stage  in  the  brain  since  neurons  have  a  limited
glycolytic  capacity,  making  them  highly  dependent  on  aerobic  OXPHOS  to  fulfil  their
energetic requirements [108].
Mitochondrial dysfunction is at the centre of many metabolic disorders, such as obesity and
T2DM. It is widely believed that these disorders can be avoided by regular exercise and
restricted food intake [109–110]. Imbalanced energy homeostasis is characteristic of obese and
T2DM patients. Interestingly, metabolic inflexibility can already be observed in pre-diabetic
individuals suffering from insulin resistance [111], limiting the ability to switch from fatty acid
breakdown to fat storage after a meal, and vice versa [112]. Diverse mitochondrial parameters
vary between insulin-resistant and insulin-sensitive subjects, such as mitochondrial number,
structure, and function. This suggests that mitochondrial dysfunction might contribute to
metabolic inflexibility and insulin resistance [113].
Chronic overnutrition and physical inactivity are major risk factors for insulin resistance and
T2DM. Recent research indicates that overnutrition generates an increase in hydrogen
peroxide (H2O2) emission from mitochondria, ultimately decreasing insulin sensitivity. Fisher-
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Wellman et al. review the principles of mitochondrial bioenergetics and redox systems’
biology, and offer new insight into how H2O2 emission may be linked via redox biology to the
aetiology of insulin resistance [28]. This concept is consistent with the principles of cellular
energetics and suggests that, in the absence of lifestyle (e.g., exercise) and/or dietary (e.g.,
caloric restriction) interventions designed to restore metabolic balance, pharmacological
strategies must be devised [28].
More importantly,  the dynamic behaviour was impaired in high-fat  diet-induced (HFD)
obese  mice,  accompanied  with  disturbed  mitochondrial  respiratory  function  and  de‐
creased ATP content in skeletal muscle. Altogether, mitochondria are dynamic organelles
in vivo  in skeletal muscle, and are essential in maintaining mitochondrial respiration and
bioenergetics. It appears that mitochondrial dynamics and bioenergetics in diabetic skeletal
muscle are impaired [16].  Dysfunctional mitochondrial bioenergetics and oxidative stress
exist in T1DM [114].
Disruption of mitochondrial function is also implicated in the aetiology of the disease. For
example, mitochondria of T2DM patients have reduced ETC capacities [115]. The ability of
pancreatic β-cells to regulate blood glucose levels rely on mitochondrial ATP generation.
Mitochondrial dysfunction or reduced mitochondrial number could impair the insulin-
signalling cascade. Excess mitochondrial ROS in β-cells inhibits OXPHOS, leading to a
decrease in ATP for glucokinase and the low ATP/ADP ratio will result in inactivated KATP
channels and impaired insulin secretion [15]. A decline in ATP generation affects the glycolysis
ratio, decreasing glucose, fructose, and several amino acids’ utilization [116–117], leading to
severe energetic impairment. Therefore, improving mitochondrial respiratory activity seems
to be a metabolic adjustment to circumvent injury in hepatocytes. It seems plausible that similar
decreases in ATP/ADP ratio occur in streptozotocin-treated rats, and the enhanced activity of
the respiratory chain of diabetic rats can be a consequence of these decreased ratios [101].
Pre-diabetes, a risk factor for type 2 diabetes development, leads to metabolic changes at a
testicular level. Every year, about 5–10% of the individuals with pre-diabetes become diabetic
[118], and population habits may increase these rates. Adenylate energy charge was decreased
in pre-diabetic rats, as were ATP and ADP levels. Conversely, AMP levels were increased,
evidencing a decreased ATP/AMP ratio. Testicular mitochondrial function was compromised
by inhibiting the PGC-1α/Sirt3 axis and the mtDNA copy number, decreasing respiratory
capacity, and increasing oxidative stress in pre-diabetes [119].
3.4. OXPHOS disorders
OXPHOS disorders can be classified genetically according to whether the primary defect is in
the nuclear or mitochondrial genome, as well as by the pathway primarily affected. There
remains a considerable lack of understanding of the pathogenic mechanisms involved in
clinical symptoms and the deterioration. The central role of OXPHOS in metabolism suggests
that many features are related to abnormal metabolic consequences of the defects.
In addition, OXPHOS defects can be tissue specific, due to the variable metabolic thresholds
for the different OXPHOS enzyme complexes in each tissue [120]. Tissue specificity may limit
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the systemic effect of metabolic changes while still inducing marked abnormalities within the
affected tissue. There are, however, likely to be many contributing factors including tissue-
specific expression of nuclear OXPHOS genes, different metabolic needs of a tissue (for
example, burst activity seen in some neurons versus cells with predominantly continuous
biosynthetic functions), and tissue-dependent segregation of heteroplasmy [121].
The treatment of patients with OXPHOS disease remains very limited, but counteracting the
most damaging metabolic changes may be beneficial in some patients, and is the mainstay of
treatment at present. An inability of mitochondria to supply sufficient ATP to meet cellular
needs is often assumed to be the primary effect of mitochondrial disease mutations [122].
3.5. Mitochondria and neurodegenerative diseases
The neurodegenerative diseases are a key health issue because they are profoundly debilitating
[123]. In the past decade, the genetic causes underlying many familial neurodegenerative
disorders, such as Huntington’s disease (HD), Parkinson’s disease (PD), Alzheimer’s disease
(AD), dominant optic atrophy, Friedreich ataxia, amyotrophic lateral sclerosis, and Leber’s
hereditary optic atrophy have been elucidated. However, the common pathogenic mecha‐
nisms of neuronal death are still largely unknown. Mitochondrial dysfunction has emerged as
a potential ‘lowest common denominator’ linking these disorders [124]. Oxidative damage to
mitochondrial membranes, enzymes, and the ETC components, culminate in impaired
mitochondrial ATP production and facilitated MPTP opening [125]. Mitochondria play
multiple roles in the maintenance of neuronal function under physiological and pathological
conditions [126].
Brain function is almost totally dependent on a continuous supply of glucose and oxygen.
Although the brain represents only 2% of the body weight, it receives 15% of the cardiac output,
and consumes 20% of total body oxygen and 25% of total body glucose [127]. A high aerobic
capacity of the brain is required for the mitochondria to generate sufficient ATP to maintain
and restore ion gradients across the enormous area of plasma membrane, to maintain the
compartmentation of neurotransmitters, and to drive exocytotic and endocytotic synaptic
vesicle cycling [126]. Given the brain’s high energy requirements, any decline in brain
respiratory chain enzyme complexes’ activity with ageing could have a significant impact on
brain function, as well as on the aetiology and progression of age-associated neurodegenera‐
tive disorders [128–130].
An aged brain has a decreased capacity to produce ATP by OXPHOS and this becomes limiting
under physiological conditions in aged individuals. The impairment of brain mitochondrial
function in ageing is mainly due to decreased electron transfer rates in complex I and IV [131].
Previous results have shown an impairment of complex I activity in brain mitochondria of
aged rats which was ascribed, in part, to oxidation of cardiolipin [132]. The age-associated
alterations to brain mitochondrial cardiolipin were prevented by treatment of aged rats with
melatonin [133]. It is reasonable to assume that melatonin’s ability to prevent the age-related
alterations of mitochondrial bioenergetic parameters in rat brains, could be ascribed (in
addition to other factors) to its protective effect against cardiolipin peroxidation. Thus, the
effect of long-term administration of melatonin against the age-dependent mitochondrial
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oxidative damage could be accompanied by an improvement of mitochondrial bioenergetics
and brain function, and therefore to health in general [128].
Deficiency in complex IV activity may be a crucial factor in the aetiology, progression, and
prevalence of several neurodegenerative diseases associated with ageing, in particular AD.
The results may prove useful in elucidating the molecular mechanisms underlying mitochon‐
drial dysfunction associated with the brain’s ageing process, and may have implications in the
aetiopathology of age-associated neurodegenerative disorders, and in the development of
potential treatment strategies. Melatonin treatment may represent a valid therapeutic strategy
for combating brain ageing process and age-related neurodegenerative disorders, in which
complex IV deficiency and oxidation/depletion of cardiolipin could play a critical role [128].
In recent years, the field of neurometabolism has been greatly amplified by the recognition
that bioenergetic dysregulation may be a critical pathophysiological factor in diseases of the
nervous system [130]. Indeed, there is increasing appreciation for the concept of energy failure
— principally from mitochondrial dysfunction — as a key mechanism resulting in neuronal
death seen in neurodegenerative diseases [134].
Previous studies have suggested that mitochondrial dysfunction plays a central role in the
pathogenesis of neurodegenerative disorders, including AD [135]. Alzheimer’s pathology is
accompanied by a decrease in expression and activity of enzymes involved in mitochondrial
bioenergetics, which would be expected to lead to compromised ETC complex activity and
reduced ATP synthesis [136]. Mitochondrial bioenergetic deficit precedes Alzheimer’s
pathology; in addition to the lowered mitochondrial bioenergetic capacity, impairment of
OXPHOS is associated with increased free radical production and the resultant oxidative
damage. Overproduction of ROS and higher oxidative stress is characteristic of brains from
AD [137]. Mitochondria and brain bioenergetics are increasingly thought to play an important
role in AD [138]. In summary, mitochondrial dysfunction and deficits in bioenergetics occur
early in pathogenesis and precede the development of observable plaque formation of AD.
Mitochondrial dysfunction provides a plausible mechanistic rationale for the hypometabolism
in the brain that precedes AD diagnosis and suggests therapeutic targets for prevention of AD.
Further, the age of reproductive senescence markedly exacerbated mitochondrial and bioen‐
ergetic dysfunction, which is coincident with marked increases in AD pathology. In addition,
one consequence of oxidative damage to mtDNA may be impairment of mitochondrial
respiratory capacity. Mitochondrial DNA damage is associated with reduced mitochondrial
bioenergetics in Huntington’s disease. HD cells may be more dependent on glycolysis than
respiration to compensate for ATP production [139]. A number of studies have identified
mitochondrial abnormalities within neuronal cell bodies in progressive multiple sclerosis,
leading to a deficiency of mitochondrial respiratory chain complexes or enzymes [140].
3.6. Mitochondria and cancer
Cancer cells exhibit large varieties of metabolic changes which are associated with alterations
in mitochondrial structure, dynamics, and function. Mitochondria can regulate tumour growth
through modulation of the TCA cycle and OXPHOS, and are also crucial in controlling redox
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homeostasis in the cell, inducing them to be either resistant or sensitive to apoptosis. All these
reasons locate mitochondria on centre stage in understanding the molecular basis of tumour
growth [141]. A change in cellular bioenergetics is one of the key hallmarks of cancer. The
Nobel prize-winning German physician and scientist, Otto Warburg, discovered that mito‐
chondria in cancer cells do not efficiently generate energy; that almost all neoplastic cells
demonstrate enhanced uptake and utilization of glucose for glycolysis to generate ATP. While
increased glycolytic flux may provide some benefit to cancer cells by increasing ATP produc‐
tion, recent studies suggest that it is advantageous mainly because it generates chemical
‘‘building blocks’’ required for the anabolic processes that must occur prior to cell division
[142]. The most glycolytic tumour cells were found to be most resistant to therapy, and most
aggressive in metastasis [143–144].
Altered metabolism was among the first cancer biomarkers [145]. Nevertheless, the notion that
glycolysis is a universal feature of aggressive tumour growth, and that OXPHOS is counter-
productive to tumorigenesis still pervades the literature [146]. There is accumulating evidence
that mitochondrial metabolism plays an essential role in tumour cell proliferation. Growing
tumours alter their metabolic profiles to meet the bioenergetic and biosynthetic demands of
increased cell growth and proliferation [147–149].
Warburg proposed that cancer could originate from the sole inhibition of respiration in human
cells, but are the mitochondria of cancer cells dysfunctional? Different studies have indicated
that OXPHOS is capable of synthesizing ATP in cancer cells, albeit with a low efficiency [150].
To survive under conditions of glucose limitation, tumour cells use OXPHOS to derive energy
from the amino-acids, glutamine, and serine. This process (glutaminolysis) has been demon‐
strated to occur in multiple types of cancer cells [142,151–153]. Deregulated energetics is a
hallmark of malignancy, but metabolic heterogeneity among individual tumours is unknown.
A study by Caro et al. [154] demonstrates that a subset of lymphomas is defined by reliance
on mitochondrial energy generation and is selectively killed when this pathway is impaired.
Collectively, these studies illustrate how differences in mitochondrial economy, bioenergetic
reserve capacity, and autophagy regulate health and disease. It is now also becoming clear that
physiological processes such as cell differentiation are associated with profound changes in
cellular bioenergetics, including reserve capacity [155]. The challenge for us is to continue to
strive to understand more fully how bioenergetics regulates cell and tissue function. Certainly,
this would place us in the best position to develop better and more targeted therapies [40].
Numerous studies on cancer cell bioenergetics evidence a large variability in the relative
contribution of glycolysis and OXPHOS to cellular ATP production. The corresponding
differences in the capacities for glycolysis and OXPHOS demonstrate that there is a cancer-
specific metabolic remodelling caused by a combination of genetic and environmental factors.
The dogma that cancer cells use solely glycolysis is no longer valid; as such, a detailed
bioenergetic characterization of each type of tumour must be performed in order to develop
adequate treatments. The growing interest in the mitochondrion in cancer research could lead
to the development of adapted metabolic therapies that might also serve to treat mitochondrial
diseases [151].
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The differences in mitochondrial function between normal cells and cancer cells may offer a
unique potential for the design of anticancer agents that deliver mitochondrial targeting drugs
to selectively kill cancer cells. The journal Science revealed that bioenergetics was the core of
malignant transformation of tumour [156], and abnormal energy metabolism was concluded
as one of the 10 most notable features of cancer cells by the journal Cell [157] — bioenergetics
dysfunction is becoming the cornerstone for understanding the pathophysiology of mitochon‐
drial diseases [40]. Here, we summarize the metabolic changes of cancer cells.
In cancer cells, anabolism is enhanced, both glucose and glutamine are important carbon
sources which are metabolized for the generation of energy, and anabolic precursors, heavily
consumed by cancer cells, are early precursors of non-essential amino acids. This process
predominates in cancer cells rendering glutamine an essential amino acid and the source of
tricarboxylic acid (TCA) cycle-derived anabolic metabolites. Mitochondrial dysfunction may
lead to the activation of HIF-1, therefore triggering the hypoxia pathway in the tumourigenic
process. The inability of mitochondria to provide enough ATP for cell survival under hypoxic
conditions, results in up-regulation of the glycolytic pathway. This occurs by induction of
HIF-1, which not only stimulates key steps of glycolysis but also suppresses mitochondrial
respiration in cancer cells, therefore, modulating the reciprocal relationship between glycolysis
and OXPHOS. The switch between glycolysis and OXPHOS is controlled by the relative
activities of pyruvate dehydrogenase (PDH) and lactate dehydrogenase (LDH). HIF-1
inactivates PDH through pyruvate dehydrogenase kinase 1 (PDK1) induction, resulting in
suppression of the Krebs cycle and mitochondrial respiration. In addition, HIF-1 stimulates
the expression of lactate dehydrogenase A, which facilitates the conversion of pyruvate to
lactate. As a result, mitochondrial contribution to ATP synthesis declines, although the
mitochondria might remain functionally intact [158] (Figure 2).
Glucose is mostly phosphorylated by hexokinase II (HKII) in cancer cells, which is up-
regulated as its gene promoter sensitive to typical tumour markers such as HIF-1 and has easy
access to ATP being more strictly bound to the mitochondria. HKII plays a pivotal role in
bioenergetic metabolism, phosphorylates glucose using ATP synthesized by OXPHOS, and
releases the product ADP in close proximity of the ANT to favour ATP re-synthesis within the
matrix. Its product, Glucose-6-P, is only in part oxidized to pyruvate. This, in turn, is mostly
reduced to lactate being both LDH and PDK1 up-regulated. A significant part of Glucose-6-P
is used to synthesize nucleotides that also require amino acids and glutamine. Glutaminolysis
(breaking down glutamine into α-ketoglutarate (α-KG)) generates malate which, through the
malic enzyme, will give rise to NADPH that can be used to fuel lipid biosynthesis, and
oxaloacetate (OAA), which will generate citrate, which is necessary for lipid biosynthesis.
Citrate in part is diverted from the TCA cycle to the cytosol, where it is a substrate of citrate
lyase, which supplies acetyl-CoA for lipid and phospholipid synthesis that also requires
NADPH. The reprogramming of mitochondrial metabolism in many cancer cells comprises
reduced pyruvate oxidation by PDH followed by the TCA cycle, and increased anaplerotic
feeding of the same cycle, mostly from glutamine. This also increases the free fatty acids’
uptake, therefore β-oxidation is pushed to produce acetyl-CoA. In cancer cells, many signals
can converge on the mitochondrion to decrease the mitochondria permeability transition
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(MPT), with consequent enhancement of apoptosis resistance. ROS can enhance Bcl-2 and may
induce mtDNA mutations. As indicated, ROS in many cancer cells are over produced.
Interestingly, studies have also shown that the Δψm is approximately 60 mV higher in carci‐
nomas as compared to their normal controls, which also contribute to the increased ROS [158]
(Figure 2).
Figure 2. Schematic illustration of metabolic reprogramming frequently occurring in cancer cells, compared with mito‐
chondrial metabolism in normal cells. Cancer cells showed increased glycolysis, pentose phosphate pathway, gluta‐
mine consumed, anabolism, Δψm, and ROS generation, and reduced TCA cycle flux, respiratory complex activities,
MPT, and apoptosis.
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4. Qi-deficiency and mitochondrial diseases
Under normal circumstances, the body is under conditions in which the viscera are coordi‐
nated, Qi and blood are in harmony, and it is in a state of equilibrium known as “both Yin and
Yang in equilibrium”. If this balance is broken, the “Yin and Yang in imbalance” appears; this
weakens the body’s responses against disease, and the disease will later attack. Just like the
Inner Canon of the Yellow Emperor says: “If the vital Qi exists in your body, the pathogenic
factors won’t disturb you”. “If the various pathogenic factors attack the body together, Qi
deficiency must occur”. “wind, rain, hot or cold, will not lead to Qi deficiency alone, only the
pathogenic factor won’t hurt the human”, these indicate the important role of the vital Qi in
the fight against pathogenic factors. The so-called “vital Qi” refers to the body’s primordial
Qi, necessary to the body’s normal functioning and ability to stay healthy; “pathogenic factors”
refers to various contributing factors in illnesses. The body’s vital Qi is the root cause, the
pathogenic factors that cause mitochondrial diseases are symptoms.
Since Qi-deficiency is the inherent basis of mitochondrial diseases, Qi-invigorating herbal
medicines and prescriptions (QIHMP), therefore, can prevent the occurrence of mitochondrial
diseases according to TCM theory. Qi-invigorating herbal medicines (QIHM) are a class of
herbs that can tonify the viscera and Qi of the human body, improve Qi-deficiency syndromes,
enhance the body’s function, improve disease resistance, have the effects of tonifying five
internal organs, calming the mind, regenerating muscles, aiding resistance to cold and heat,
and anti-ageing. Commonly-used QIHM include ginseng, astragalus, Codonopsis, Atractylo‐
des, American ginseng, Chinese yam, liquorice, jujube etc., all rich in polysaccharides, which
provides the material basis for improving Qi-deficiency syndrome and energy metabolism.
Studies have shown that all QIHM have the effects of improving exercise capacity, anti-fatigue,
anti-oxidation, anti-hypoxia, anti-ageing, scavenging ROS, anti-apoptosis, improving immune
function, and other benefits. The common regular pharmacological effects of these QIHM are
closely related to the mitochondrial function; it is reasonable to assume that all QIHM
invigorate Qi through the mitochondrial pathway, which provide evidence for Qi-invigorating
therapy used for mitochondrial diseases.
Still, the number of therapeutic approaches for mitochondrial diseases is severely limited in
Western medicine. How might we jump-start the search for treating the diseases? One
promising approach might be TCM. If mitochondrial dysfunction is as important a factor in
the diseases as proposed in this essay, then Qi-invigorating therapy should be as likely to target
mitochondrial energetic function. If so, we might be able to modulate mitochondrial function
by screening traditional Chinese therapies. These could then be applied to treating the
mitochondrial diseases. If this strategy proves successful, then it may have been prescient that
a major concept in the parlance of TCM is “Qi”, which we propose that “Qi” is “bioenergy” [25].
According to TCM theory, all kinds of diseases and ailments are born from Qi; Qi refers to a
kind of refined nutritive substance that constitutes the human body, and is the most basic
motive force, maintaining life’s functional activities. Qi is fundamental to our body; both life
and death of humans depends on Qi. Qi is often described in the West as energy, or vital energy.
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Therefore, life’s activities depend on Qi. Qi underpins the basic theory of TCM and acts as its
cornerstone. Qi has been used as a healing technique in China for 4000 years. Chinese people
from all walks of life seek relief through a rebalancing of their Qi for ailments, from colds to
cancer. From the Chinese perspective, Qi is the origin of true strength and power as well as
genuine health — body, mind, and soul. In order to have good health you must have sufficient
Qi. If there is not enough Qi (Qi-deficiency), one or more organs can become imbalanced and
develop energy function disorders. Impaired mitochondrial ATP formation may be the key
characteristic of Qi-deficiency.
The author found that Qi-deficiency led to a marked fall in cellular ATP, and a rise in cellular
AMP. Qi-deficiency is the common cause of mitochondrial diseases and can lead to mitochon‐
drial bioenergetics dysfunction, and Qi-invigoration is the basic principle for treatment of Qi-
deficiency [26]. As ATP, an energy-rich biomolecule, is universally used for energizing cellular
activities, the “Qi-invigorating” action may be mediated by the enhancement of mitochondrial
ATP generation. In this regard, our previous studies show that all four widely used QIHM
(including ginseng, astragalus root, pilose asiabell root, and white atractylodes rhizome) can
increase ATP levels of liver cells in vivo. The concept of “Qi” in TCM is closely related to
bioenergy in modern medicine; we propose a hypothesis that Qi is bioenergy according to both
the ancient concept of Qi and modern bioenergetics [25]. Based on our findings, Qi-invigorat‐
ing representative prescription Sijunzi decoction [26] and QIHM can enhance the mitochon‐
drial ATP generation capacity, and they have a good effect in the treatment of Qi-deficiency
syndrome. It is plausible that mitochondrial diseases involve an improvement of cellular
energy status which can be accomplished by Qi-invigoration. We believed that the up-
regulation of cellular activities by “Qi-invigoration” in Chinese medicine requires an increased
supply of ATP, which is in turn largely supported by mitochondrial OXPHOS. Qi-invigorating
prescriptions and herbal medicines have a good effect in improving energy metabolism.
Mitochondrial diseases are a result of a decline in “Qi” (Qi-deficiency), and lead to deteriora‐
tion in functions; therefore, Qi-invigorating therapy for mitochondrial diseases is logical.
5. Qi-invigorating therapy and prevention and treatment of mitochondrial
diseases
“Qi theory” in Chinese medicine is profound. Investigation into the scientific connotations of
the concept “Qi” and the mechanism of Qi-invigorating herbal medicines and prescriptions
(QIHMP) by modern science over the past decade, have become a key point for the moderni‐
zation of TCM.
“Qi” is closely related to “bioenergy”, both “Qi” in TCM and “bioenergy” in the life sciences
have played an important role. Qi-deficiency can lead to energy metabolism dysfunction,
which is a common feature of mitochondrial diseases in turn, and this confirmed that Qi-
deficiency is the basis of the incidence of mitochondrial diseases; Qi-invigoration is the basic
principle for treating Qi-deficiency, Qi-invigoration is also able to improve mitochondrial
bioenergetics. Logically, therefore, Qi-invigoration can prevent mitochondrial diseases. TCM
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usually interpret the properties of herbal medicines with Qi, and has become one characteristic
of treating dieases, this can be understood as “regulating Qi by Qi”.
Therefore, the broad and profound TCM Qi theory and the most recent research of mitochon‐
drial diseases were integrated, the mechanism of Qi-invigorating therapy for mitochondrial
diseases was clarified from the perspective of improving mitochondrial bioenergetics, and a
novel perspective and new hope were provided for the prevention and treatment of mito‐
chondrial diseases with original academic ideas.
QIHMP have a positive effect in improving the energy metabolism; for example, the Qi-
invigorating representative prescriptions Sijunzi Decoction (SD) was able to improve mito‐
chondrial function by enhancing cellular bioenergetics and had the pharmaceutical activities
of mitochondrial protection [26]. Panax ginseng is one of the most popular QIHM and has been
used to promote health, vitality, and longevity in China for millennia. Panax ginseng invigorates
Qi by improving energy metabolism and boosting energy levels in different body parts to delay
ageing [159]. QIHMP can help in boosting the level of vital energy in the body. The studies
provide scientific evidence for the mechanism of Qi-invigoration in TCM, which is achieved
by improving mitochondrial energy metabolism. As deficiency of Qi is thought to be the cause
of mitochondrial diseases in TCM, this property is especially important for using Qi-invigor‐
ating therapy to counteract mitochondrial diseases.
The central therapeutic action of QIHMP is their ability to preserve Qi. One direction that
scientists have recently explored is the mitochondrial dysfunction theory. Astragalus membra‐
naceus is the most popular Qi-invigorating herbal medicine in TCM, is often used in formulas
for Qi-deficiency characterized by limb weakness, fatigue, lack of appetite, and dizziness.
Astragalus polysaccharides (APS), an important bioactive component of Astragalus membra‐
naceus, have been applied in the prevention and treatment of cancer in TCM. APS can ameli‐
orate vacuolar degeneration of mitochondria and fragmentation of mitochondrial cristae of
hepatocytes in insulin-resistant mice, which indicates the mitochondrial dysfunction and the
protective effect of APS [160]. Our preliminary studies indicate that APS can protect mito‐
chondria by scavenging ROS, inhibiting lipid peroxidation and mitochondrial swelling, and
increasing the activities of antioxidant enzymes [161]. We proposed that APS perhaps ulti‐
mately ameliorate mitochondrial dysfunction by improving energy metabolism; this may be
the hypothetical anticancer and cancer-preventive mechanism of APS.
In the book Cancer — Cares, Treatments and Preventions, we demonstrate that APS play a role
in cancer prevention by improving mitochondrial energy metabolism. We also discovered
accidentally that APS could increase the levels of ATP and total adenylate pool (TAP) in
hypoxic liver cells, reduce AMP levels, increase ATP/ADP, ATP/AMP ratios and adenylate
energy charge (AEC) (i.e., increase cellular bioenergetics), and feedback inhibit OXPHOS by
reducing the liver mitochondrial respiratory control rate (RCR), respiratory states 3, and P/O
ratio, to regulate energy generation. We found that hypoxia leads to a marked fall in cellular
ATP and ADP, and a rise in cellular AMP. Cellular ATP levels are closely linked to mitochon‐
drial function, which is regulated perhaps by AEC. APS stimulated an increased output of
ATP and can further decrease state 3 respiration, RCR, and P/O ratio of liver mitochondria
compared to a normal group — we consider that this is the result of feedback inhibition by
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improving mitochondrial energy metabolism and the bioenergetic level [156]. The mitochon‐
drial energy state can retro-regulate the nuclear-encoded energy genes. The changes in
mitochondrial respiratory chain activity are followed by changes in “energy-state messengers”
which include ROS (such as the diffusive H2O2), mitochondrial and cytosolic calcium, NADH/
NAD+, ATP/ADP, GTP, AMP, cyclic AMP (cAMP), Δψm, and ΔpH [162]. APS was able to
improve mitochondrial function by enhancing cellular bioenergetics and had the pharma‐
ceutical activities of mitochondrial protection by scavenging ROS, inhibiting lipid peroxida‐
tion, and increasing the activities of antioxidant enzymes. The study provides scientific
evidence for the pathophysiological mechanism of mitochondrial diseases, which is achieved
by improving mitochondrial bioenergetics.
The Mitchell theory has been unable to explain this phenomenon; in recent years, studies have
shown that the Mitchell theory has limitations for OXPHOS in eukaryotic cells. The Mitchell
theory implies the proton motive force (Δp) across the inner mitochondrial membrane as the
energy-rich intermediate of OXPHOS. Δp is composed mainly of an electrical (Δψm) and a
chemical part (ΔpH) and generated by the respiratory chain complexes I, III and IV. The free
energy of electron transport of the mitochondrial proton pumps is sufficient to create a Δp of
240 mV, most of which (>80%) represents the mitochondrial membrane potential (Δψm) and a
smaller part ΔpH. The passive proton permeability of biological membranes or the basal
proton leak increases exponentially at Δψm values above 130 mV. At Δψm values above 140
mV, the formation of reactive oxygen species (ROS) increases exponentially. The rate of F0F1-
ATP synthase is saturated and maximal at Δψm values of about 120 mV. Thus Δψm values above
140 mV are not required for maximal rates of ATP synthesis. Instead at high Δψm values, the
efficiency of OXPHOS decreases due to increased basal proton leak of biological membranes.
In addition, part of oxygen will be converted into harmful ROS. From both an economic and
health point of view, multicellular organisms require a mechanism that does not rely on the
Mitchell theory, while maintaining the Δψm at reasonably low levels (120–140 mV), thereby
optimizing the efficiency of OXPHOS and can suppress the occurrence of mitochondrial
diseases. Surprisingly, the German scientist Kadenbach et al. propose a new mechanism that
does not rely on the Mitchell theory, in which high ATP/ADP ratio feedback inhibits CcO
(complex IV), and maintains a low Δψm value, thereby preventing ROS generation and
maintaining high efficiency of OXPHOS — the mechanism represents the new extension of
Mitchell theory, known as the “The second mechanism of respiratory control” [163].
According to recent studies, the authors propose that QIHMP, such as Panax ginseng, Astragalus
membranaceus, and the Sijunzi Decoction can improve mitochondrial bioenergetics, while
higher levels of bioenergy will feedback inhibit OXPHOS. These studies enriched Kadenbach’s
“New extension of the Mitchell Theory” through multiple bioenergetic parameters; this not
only provides the strongest evidence for the contention that “The second mechanism of
respiratory control represents new extension of the Mitchell Theory for OXPHOS”, but also
proposes how to improve bioenergetic levels of cells by QIHMP intervention. A theoretical
basis and novel ideas were provided for the research and development of new drugs for
mitochondrial diseases, using mitochondrial bioenergetics as a target. Therefore, the authors
propose that improving mitochondrial energy metabolism and bioenergetic levels are the
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possible biological mechanisms to prevent and treat mitochondrial diseases. Based on the
current research on mitochondrial protection and improvement of energy metabolism by
QIHMP, we prove that QIHMP act by improving the bioenergetic state, and have activities of
making the body more energetic and dynamic. Qi-invigoration is achieved through the
mitochondrial energy metabolic pathway. This provides a scientific basis to clarify why Qi-
invigorating therapy in Chinese medicine is suitable for treating mitochondrial diseases from
a mitochondrial bioenergetic perspective.
QIHMP have a unique advantage in the process of counteracting mitochondrial diseases;
intervention can be performed by multi-level, multi-channel, and multi-target methods,
focusing on increasing the vital Qi of our body, helping to improve symptoms and signs, to
improve the life quality of patients, and prolong survival. This is one of the characteristics of
TCM for the prevention and treatment of mitochondrial diseases, and Qi-invigorating therapy
plays an important role in the comprehensive treatment of mitochondrial diseases. Qi-
invigorating prescriptions (QIP), the combination of commonly used QIHM, are used for the
treatment of Qi-deficiency under the guidance of Qi-invigorating therapy. If doctors can focus
on pathogenesis features of Qi-deficiency at the different levels of the main symptom,
accompanying symptoms, deteriorated case syndromes, and synergize with Chinese herbal
medicines, such as warming Yang, nourishing Yin, calming the nerves, reducing phlegm,
invigorating the circulation of blood, astringing, clearing heat medicines, and others, based on
benefiting Qi and complementing deficiency, so that the monarch and ministerial drugs
synergize in an orderly fashion, just match the symptoms, then QIP can be widely used in a
variety of clinical disorders.
In summary, mitochondria are responsible for the generation of cellular energy and are
believed to play a central role in ageing and mitochondrial diseases. In vivo experiments have
shown that almost all QIHM could promote mitochondrial ATP generation in various types
of tissue including the brain. We propose in this chapter that Qi-invigorating therapy can be
used for the prevention and treatment of mitochondrial diseases for the first time in the world,
and that good medical effects may thereby be attained.
6. Conclusion and perspectives
This chapter has focused on the growing body of evidence that mitochondria, although the
major source of ATP, are also intimately involved in the aetiology of numerous human
pathologies. Therefore, effective prevention and treatments for mitochondrial diseases has
become a pressing issue. It is evident that Qi-invigorating therapy will furnish a greater efficacy
and selectivity for these diseases, but will lead to fewer undesirable side effects. It has been
over 50 years since the first description of a patient with a mitochondrial disease [2]; with the
rapid development in mitochondrial medicine, mitochondrial disease research focused on
unravelling the aetiology of mitochondrial dysfunction for the first 30 years. Currently, the
most important focus is on providing a preventive method or cure for these devastating
diseases.
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A rational way to combat mitochondrial dysfunction is to correct the bioenergetic alterations
seen at the cellular level. This approach is theoretically applicable in all mitochondrial diseases.
Many research groups around the world have established ways to manipulate mitochondrial
pathology in cellular models. Now is the time to test these therapies in vivo. Despite the
apparent lack of therapy, the confirmation of a mitochondrial disease is important to prevent
secondary mitochondrial dysfunction as seen in malnutrition or deconditioning. This chapter
gives an overview of some potential breakthroughs and the hopes in pursuit of the first
effective prevention and treatment for mitochondrial diseases by Qi-invigorating therapy.
There seems to be light at the end of the tunnel, although currently it is difficult to predict
when such treatment will become available. The primary cause of most mitochondrial diseases
is a multifaceted aetiology; hence, efforts to develop effective drugs should be devoted to the
design of Qi-invigorating prescriptions that work in synergy to protect the mitochondria.
TCM will provide new philosophical thinking and selective application for modern medicine.
TCM is full of ancient Chinese wisdom and philosophical speculation, it advocates “preventive
treatment of disease”, and Chinese Preventive Medicine benefits a lot from it. Chinese
medicine views the human body as a whole, focusing on the adjustment of inner balance, pays
more attention to patients than to the diseases, and the systemic therapy was used for more
than 2,000 years.
Developmental ideas of traditional Chinese medical philosophy and modern Western
medicine are converging. The current health concepts and medical models are profoundly
changed; from the perspective of developmental trends, Western medicine also began to pay
attention to the disease prevention, self-care, individualized treatment and environmental
influence on the disease, transition from disease-centred to patient-centred, which match the
concept “disease prevention is the primacy”, “man is an integral part of nature”, and is
consistent with the essential characteristics of “overall concept” and “treatment based on
syndrome differentiation” in TCM for thousands of years. Chinese medicine believes that the
health of people is interrelated with nature and is under its dominance, that people should
preserve harmony with nature, that the human body is a systemic whole, that the relationship
between the main viscera can be described by the five elements theory, and that health depends
on the balance of Yin and Yang. TCM guides doctors in the prevention and treatment of disease
through the system’s theory.
However, not all clinical questions can be explained by TCM’s theory; the new concepts and
breakthroughs of modern Western medicine are sometimes difficult to integrate into the
theoretical framework of TCM. Therefore, there is an urgent need to achieve exchanges and a
convergence between the two systems, to translate the theory of TCM into the language of
modern life sciences.
Qi theory is the core of the basic theory in TCM, the concept of “Qi” is complex and messy,
the connotation of Qi is colourful, the extension of Qi is unlimited, and Qi has become an
enigma of Chinese medicine. Since there is no concept of “Qi” in modern medicine, it is the
biggest difference between Chinese and Western medicine, which leads to obstacles for the
mutual communication between the two medical systems. The essence of Qi is extremely
important and is an unavoidable major scientific problem to the modern development of TCM.
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So the nature of “Qi” should become the key scientific issue to be resolved first. This chapter
may provide a breakthrough point to reveal the essence of Qi in TCM, and to achieve further
genuine integration with Western medicine.
It is not easy to do this, but it is very important for the entrance of TCM into the international
academic community, and then to endow it with vitality in the future. The purpose of both
Chinese and Western medicine is to maximize health protection; we should gradually break
through the barriers between Chinese and Western medicine, and give full play to their
respective advantages. On the one hand we want to make full use of new theoretical ideas and
methods, new technologies, and multi-disciplinary cross-penetration of modern Western
medicine, accelerating innovation of traditional medicine theory and technology. On the other
hand, we should give full play to the characteristics and advantages of traditional medicine in
the concepts of life, health, the medical model, and other aspects, provide more treatment ideas,
and methods and means for modern Western medicine. The material basis and mechanism of
Chinese materia medica are clarified on the basis of efficacy.
We think it is possible to build a modern medical system which fuses the advantages of both
Chinese and Western medicine. This system will be inclusive and eclectic, not rest on its laurels;
both based on history and look to the future; and will be superior to TCM, and possibly also
superior to current Western medicine. If the challenges are shared, the challenges will be
divided; if the results are shared, the results will be doubled.
With respect to the sacred cause (the maintenance and promotion of human health), let us have
a broader vision, more multi-dimensional thinking, and an open mind. We believe that the
convergence of traditional Chinese medicine and modern Western medicine will not only help
us to achieve better health outcomes and benefit humans’ well-being than are possible with
the simple application of either one, but also that it will be possible to open a door leading to
a wider world for us in the near future, promoting the development of the health industry.
“Qi is the root of human”, Qi is the centre of TCM from basic theory to clinical practice, Qi
theory is the core of the basic theory of TCM, Qi is also an enigma of Chinese medicine. The
essence of “Qi” is the key scientific issue needing to be resolved first; “Qi essence, the mech‐
anism of Qi-invigoration and Qi-invigorating therapy for the prevention and treatment of
mitochondrial diseases” have been systematically studied by us in the past 20 years and had
led to a series of original academic achievements. This has important scientific significance for
Chinese medicine theory and its practical application. These studies may help us to find a
breakthrough point to reveal the essence of Qi in TCM, in order to achieve genuine integration
with Western medicine and lead the development of Western medicine. We proposed the
original creative academic ideas that “Qi” and bioenergy are closely related, demonstrated
that the mechanism of Qi-invigorating action was implemented by improving mitochondrial
energy metabolism, and proposed a new scientific hypothesis for the prevention and treatment
of mitochondrial diseases by improving mitochondrial bioenergetics with Qi-invigorating
therapy.
It is hoped that the next few years will see a further convergence of Qi-invigorating therapy
with mitochondrial bioenergetics function, which will provide a comprehensive view of
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mechanisms on mitochondrial diseases. It seems likely that we are on the right track to acquire
this understanding, and that it will involve mechanisms rich in novel modern medical sciences
and old Qi ideas in TCM about mitochondrial diseases and how to counteract them. New
perspectives, new ideas, and new hopes were proposed for mitochondrial diseases.
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